Vanguard Global Advisers’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$30.3M Buy
102,610
+3,605
+4% +$950K 0.01% 504
2026
Q2
$22.5M Sell
99,005
-4,491
-4% -$800K 0.01% 553
2026
Q1
$17.9M Buy
+103,496
New +$19.2M 0.01% 568

Other funds holding CRL

Vanguard Global Advisers's CRL Position: Q3 2026 in Review

Vanguard Global Advisers increased its Charles River Laboratories (CRL) stake by 3.6% in Q3 2026, buying an estimated $950K and bringing the position to 102,610 shares worth $30.3M. The position accounts for 0.01% of the portfolio, ranked #504.

Vanguard Global Advisers first reported a position in CRL in Q1 2026 and has held it in 3 quarters since. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Vanguard Global Advisers held 102,610 shares of Charles River Laboratories worth $30.3M as of Q3 2026.
  • Vanguard Global Advisers bought 3,605 Charles River Laboratories shares in Q3 2026, an estimated $950K.
  • Charles River Laboratories made up 0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #504 holding.
  • Vanguard Global Advisers first reported a position in Charles River Laboratories in Q1 2026 and has held it in 3 quarters since.
  • 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.